Patent review of cannabinoid receptor type 2 (CB 2 R) modulators (2016-present).

Autor: Kosar M; Laboratorium für Organische Chemie, Eidgenössische Technische Hochschule Zürich, Zürich, Switzerland., Mach L; Medicinal Chemistry, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) Berlin, Berlin, Germany., Carreira EM; Laboratorium für Organische Chemie, Eidgenössische Technische Hochschule Zürich, Zürich, Switzerland., Nazaré M; Medicinal Chemistry, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) Berlin, Berlin, Germany., Pacher P; National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, MD, USA., Grether U; Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Jazyk: angličtina
Zdroj: Expert opinion on therapeutic patents [Expert Opin Ther Pat] 2024 Aug; Vol. 34 (8), pp. 665-700. Date of Electronic Publication: 2024 Jul 02.
DOI: 10.1080/13543776.2024.2368745
Abstrakt: Introduction: Cannabinoid receptor type 2 (CB 2 R), predominantly expressed in immune tissues, is believed to play a crucial role within the body's protective mechanisms. Its modulation holds immense therapeutic promise for addressing a wide spectrum of dysbiotic conditions, including cardiovascular, gastrointestinal, liver, kidney, neurodegenerative, psychiatric, bone, skin, and autoimmune diseases, as well as lung disorders, cancer, and pain management.
Areas Covered: This review is an account of patents from 2016 up to 2023 which describes novel CB 2 R ligands, therapeutic applications, synthesis, as well as formulations of CB 2 R modulators.
Expert Opinion: The patents cover a vast, structurally diverse chemical space. The focus of CB 2 R ligand development has shifted from unselective dual-cannabinoid receptor type 1 (CB 1 R) and 2 agonists toward agonists with high selectivity over CB 1 R, particularly for indications associated with inflammation and tissue injury. Currently, there are at least eight CB 2 R agonists and one antagonist in active clinical development. A better understanding of the endocannabinoid system (ECS) and in particular of CB 2 R pharmacology is required to unlock the receptor's full therapeutic potential.
Databáze: MEDLINE
Externí odkaz: